Lanzarote's bilingual magazine

New-wave Botox

Techniques and materials continue to evolve, and today’s botulinum toxin injections, such as Letybo, Alluzience, or Daxxify, bear little resemblance to those used when this practice was introduced

It’s been twenty years since Botox revolutionized the medical aesthetics industry in Spain. During this time Merz Pharma, Allergan and Galderma laboratories have been the dominant players, offering treatments with similar effects and durations. But now, a new wave of botulinum toxin-based products is poised to reshape the market. Letybo, Alluzience and Daxxify, each with unique characteristics and advantages, offer patients more options than ever before for addressing facial wrinkles and fine lines.
Letybo, developed by Croma-Pharma, introduces the active ingredient botulinum toxin type A. As a new strain it has no pre-existing resistances or antibodies and offers longer-lasting effects of an average 4-6 months, making it an attractive choice for patients seeking extended results. Additionally, Letybo is approved for use in Spain, for patients up to 75 years of age, compared to the usual 65-year limit for other botulinum products. However, it is only authorised for eyebrow lifts at present and is not recommended for children under 18, during pregnancy, or while breastfeeding.
Alluzience, from IPSEN Pharma-Galderma Laboratories, is also approved for use in Spain. It distinguishes itself by being supplied in a ready-to-use liquid form. Its unique formula does not contain lactose or animal proteins, making it suitable for people who are allergic or intolerant, as well as vegans. Moreover, it promotes gentle muscle relaxation, avoiding the unnatural “frozen” appearance sometimes associated with botox treatments. And its versatility means it can be used to treat different areas of the face. Effects are visible within 24-48 hours of administration and can last up to 6 months.
Daxxify, developed by Revance Therapeutics, has received FDA approval in the United States but is still awaiting the green light in Europe. Its publicity boasts longer-lasting results, with effects lasting up to 8 months, compared with the 4-6 months of its predecessor. Its formulation uses a synthetic, stabilising peptide that doesn’t use human albumin protein or any other animal product, making it suitable for people with allergies or sensitivities. The only drawback compared to other products is that Daxxify’s injection process is reportedly rather painful.


Must Read